Optiscan Lodges Two U.S. FDA Applications, Advancing Devices Into Review
OIL: $0.155 +3.33% · MC: $162M
Optiscan says it lodged U.S. FDA applications for its InForm digital pathology and InVue precision surgery devices shortly after quarter-end, moving both into formal review; U.S. market entry remains subject to clearance. The company also signed two Mayo Clinic research agreements and launched its InSpecta veterinary device in the U.S. during the quarter.

Comments